Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | MC3R | P41968 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.57 |
| ▸ | PTGFR | P43088 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.57 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Unoprostone SCHEMBL18605546 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL1286326 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL14957866 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL2469324 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL2469329 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL1286324 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| SCHEMBL6409062 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL194651 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL22965277 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B | |
| Unoprostone SCHEMBL572177 | 1.00 | PGR (0.73) | PGRADORA3SLC6A2ADRA2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371309-A1 | OPHTHALMIC SOLUTION | SUCAMPO AG (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8853268-B2 | Ophthalmic solution | SUCAMPO AG (CH) | 2014-10-07 | — | — | US | disclosed |
| US-20140039058-A1 | OPHTHALMIC SOLUTION | SUCAMPO AG (CH) | 2014-02-06 | — | — | US | disclosed |
| US-8580851-B2 | Ophthalmic solution | SUCAMPO AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20050222265-A1 | Ophthalmic solution | SUCAMPO AG | 2005-10-06 | — | — | US | disclosed |
| US-20040076678-A1 | Comprising prostaglandin compound and viscosity-increasing compound; provides elongated duration of effect when administrated topically to eyes | SUCAMPO AG | 2004-04-22 | — | — | US | disclosed |
| EP-0730866-B1 | Treatment of optic nerve disorders with prostanoic acid compounds | R TECH UENO LTD (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0453127-B1 | Treatment of cataract with 15-keto-prostaglandin compounds | R TECH UENO LTD (JP) | 1998-08-05 | — | — | EP | disclosed |
| US-5770759-A | 13,14-DIHYDRO-15-KETO-PGF'S; VASOPRESSORS | R-TECH UENO, LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| EP-0430551-B1 | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds | R TECH UENO LTD (JP) | 1998-01-28 | — | — | EP | disclosed |
| EP-0730866-A2 | Treatment of optic nerve disorders with prostanoic acid compounds | R-TECH UENO LTD. (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5256696-A | Increase contraction of cardiac muscle | KABUSHIKIKAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 1993-10-26 | — | — | US | disclosed |
| US-5221763-A | 13,14-dihydro-15-keto-PGFs and salts | R-TECH UENO, LTD. (JP) | 1993-06-22 | — | — | US | disclosed |
| US-5212200-A | Prostaglandins | R-TECH UENO, LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| US-5166178-A | Ocular hypotensive agents | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0308135-B1 | OCULAR HYPOTENSIVE AGENTS | R-TECH UENO LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
| US-5106869-A | Vasopressor activity without ephemeral vasorelaxation; no effect on trachea, intestine | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0455264-A2 | Ocular hypotensive agents | R-TECH UENO LTD. (JP) | 1991-11-06 | — | — | EP | disclosed |
| US-5001153-A | Ocular hypotensive agents | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1991-03-19 | — | — | US | disclosed |
| EP-0308135-A2 | Ocular hypotensive agents | R-TECH UENO LTD. (JP) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371309-A1 | OPHTHALMIC SOLUTION | PTGIS, PTGIR, PTGS1 | PGR 1775/4885ADORA3 772/4885SLC6A2 1408/4885 |
| US-20050222265-A1 | Ophthalmic solution | PTGIS, PTGIR, PTGS1 | PGR 1775/4885ADORA3 772/4885SLC6A2 1408/4885 |
| US-20140039058-A1 | OPHTHALMIC SOLUTION | PTGIS, PTGIR, PTGS1 | PGR 1775/4885ADORA3 772/4885SLC6A2 1408/4885 |
| US-20040076678-A1 | Comprising prostaglandin compound and viscosity-increasing compound; provides elongated duration of effect when administrated topically to eyes | PTGIR, PTGS1, PTGER1 | PGR 1118/4885ADORA3 1282/4885SLC6A2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.